Pulmonx Corporation (NASDAQ: LUNG) is a Healthcare company (Medical - Devices) with a market capitalization of $119M. The Maz Rating grades it against the other companies in its sector.
Pulmonx Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $2.73, Pulmonx Corporation trades at 1.4x sales and 3.5x book value. Over the last twelve months it generated about $87M of revenue and a net loss of $43M. It runs a gross margin of 77.4%, an operating margin of -44.4% and a net margin of -47.9%. It shows return on equity of -98.2%, return on invested capital of -43.3% and a free cash flow yield of -21.0%. On the balance sheet: a debt-to-equity ratio of 1.65 and a current ratio of 4.05. Over the past 52 weeks the share price ranged from $1.13 to $3.25, with a beta of 0.28.
Pulmonx Corporation does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 4 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Pulmonx Corporation (LUNG) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 60.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 56.5% / 30% · Interest income / Revenue 1.51% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 60.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 56.5% / 33% · Receivables / Mkt Cap (36m) 12.9% / 49% · Interest income / Revenue 1.51% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 60.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 56.5% / 33.33% · Receivables / Mkt Cap (24m) 12.9% / 33.33% · Interest income / Revenue 1.51% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 39.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 50.6% / 33.33% · Receivables / Avg Assets (4Q) 10.0% / 33.33% · Interest income / Revenue 1.51% / 5% | Fail |
| FTSE | Debt / Total Assets 51.1% / 33.33% · (Cash+ST Inv) / Total Assets 47.8% / 33.33% · (Cash+Recv) / Total Assets 58.7% / 33.33% · Interest income / Revenue 1.51% / 5% | Fail |
No. As of September 2026, Pulmonx Corporation (LUNG) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Pulmonx Corporation is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
About 1.51% of each dividend: Pulmonx Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.